The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease

Clinical and Experimental Immunology

Volumn 148, Issue 1, 2007, Pages 32-46

  Afzali, B ^a   Lombardi, G ^a   Lechler, R I ^a   Lord, G M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Autoimmune disease; Human; Interleukin 17; Lineage commitment; Regulatory T cells; Th17; Transcription factors

Indexed keywords

ANTIINFLAMMATORY AGENT; CD40 LIGAND; GAMMA INTERFERON; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 6; NITRIC OXIDE; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; ALLERGIC ENCEPHALITIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL SURVIVAL; CELLULAR IMMUNITY; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; GRAFT VERSUS HOST REACTION; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT ALLERGY; REVIEW; RHEUMATOID ARTHRITIS; T HELPER 17 CELL;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; GRAFT REJECTION; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-17; LUPUS ERYTHEMATOSUS, SYSTEMIC; RESPIRATION DISORDERS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 33847667225     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03356.x     Document Type: Review

References (230)

1. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003; 21:139-76.
2. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994; 179:973-84.
3. Markovic-Plese S, Fukaura H, Zhang J et al. T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J Immunol 1995; 155:982-92.
4. Fossiez F, Djossou O, Chomarat P et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183:2593-603.
5. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15:297-322.
6. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17:701-38.
7. Gately MK, Renzetti LM, Magram J et al. The interleukin-12/ interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998; 16:495-521.
8. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000; 100:655-69.
9. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science 2002; 295:338-42.
10. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89:587-96.
11. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunol 2003; 4:330-6.
12. Wan YY, Flavell RA. Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc Natl Acad Sci USA 2005; 102:5126-31.
13. Ivanov II, McKenzie BS, Zhou L et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126:1121-33.
14. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16:34-8.
15. Matthys P, Vermeire K, Mitera T, Heremans H, Huang S, Billiau A. Anti-IL-12 antibody prevents the development and progression of collagen-induced arthritis in IFN-gamma receptor-deficient mice. Eur J Immunol 1998; 28:2143-51.
16. Ferber IA, Brocke S, Taylor-Edwards C et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996; 156:5-7.
17. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8.
18. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24:179-89.
19. Mangan PR, Harrington LE, O'Quinn DB et al. Transforming growth factor-beta induces development of the T (H) 17 lineage. Nature 2006; 441:231-4.
20. Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls J, van den Berg WB. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 2002; 51:102-4.
21. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233-40.
22. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24:677-88.
23. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993; 150:5445-56.
24. Yao Z, Timour M, Painter S, Fanslow W, Spriggs M. Complete nucleotide sequence of the mouse CTLA8 gene. Gene 1996; 168:223-5.
25. Li H, Chen J, Huang A et al. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci USA 2000; 97:773-8.
26. Starnes T, Broxmeyer HE, Robertson MJ, Hromas R. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol 2002; 169:642-6.
27. Lee J, Ho WH, Maruoka M et al. IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem 2001; 276:1660-4.
28. Starnes T, Robertson MJ, Sledge G et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. J Immunol 2001; 167:4137-40.
29. Shi Y, Ullrich SJ, Zhang J et al. A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 2000; 275:19167-76.
30. Yao Z, Fanslow WC, Seldin MF et al. Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3:811-21.
31. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 2003; 170:2106-12.
32. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006; 177:4662-9.
33. Shin HC, Benbernou N, Esnault S, Guenounou M. Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine 1999; 11:257-66.
34. Molet S, Hamid Q, Davoine F et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108:430-8.
35. Zhou Q, Desta T, Fenton M, Graves DT, Amar S. Cytokine profiling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide, or its FimA protein. Infect Immun 2005; 73:935-43.
36. Yao Z, Spriggs MK, Derry JM et al. Molecular characterization of the human interleukin (IL)-17 receptor. Cytokine 1997; 9:794-800.
37. Silva WA Jr, Covas DT, Panepucci RA et al. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells 2003; 21:661-9.
38. Haudenschild D, Moseley T, Rose L, Reddi AH. Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem 2002; 277:4309-16.
39. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14:155-74.
40. Ye P, Rodriguez FH, Kanaly S et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194:519-27.
41. Nakae S, Komiyama Y, Nambu A et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002; 17:375-87.
42. Attur MG, Patel RN, Abramson SB, Amin AR. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 1997; 40:1050-3.
43. Ruddy MJ, Wong GC, Liu XK et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 2004; 279:2559-67.
44. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 1999; 162:494-502.
45. Witowski J, Pawlaczyk K, Breborowicz A et al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000; 165:5814-21.
46. Woltman AMHS, Boonstra JG, Gobin SJ, van Daha MR, van Kooten C. Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol 2000; 11:2044-55.
47. Miyamoto M, Prause O, Sjostrand M, Laan M, Lotvall J, Linden A. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. J Immunol 2003; 170:4665-72.
48. Ye P, Garvey PB, Zhang P et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 2001; 25:335-40.
49. Laan M, Lotvall J, Chung KF, Linden A. IL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases. Br J Pharmacol 2001; 133:200-6.
50. Jones CE, Chan K. Interleukin-17 stimulates the expression of interleukin-8, growth-related oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells. Am J Respir Cell Mol Biol 2002; 26:748-53.
51. Yao Z, Painter SL, Fanslow WC et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995; 155:5483-6.
52. McGeachy MJ, Anderton SM. Cytokines in the induction and resolution of experimental autoimmune encephalomyelitis. Cytokine 2005; 32:81-4.
53. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther 2005; 7:29-37.
54. Schwarzenberger P, La RV, Miller A et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol 1998; 161:6383-9.
55. Pan G, French D, Mao W et al. Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol 2001; 167:6559-67.
56. Miossec P. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003; 48:594-601.
57. Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103:1345-52.
58. Hwang SY, Kim HY. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cells 2005; 19:180-4.
59. Chabaud M, Durand JM, Buchs N et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999; 42:963-70.
60. Chabaud M, Lubberts E, Joosten L, van Den BW, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001; 3:168-77.
61. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998; 161:409-14.
62. Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a 'fine-tuning cytokine' in inflammation processes. Arthritis Rheum 2001; 44:2176-84.
63. LeGrand A, Fermor B, Fink C et al. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum 2001; 44:2078-83.
64. Lubberts E, Joosten LA, van de Loo FA, van den Gersselaar LA, van den Berg WB. Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum 2000; 43:1300-6.
65. Jovanovic DV, Di Battista JA, Martel-Pelletier J et al. Modulation of TIMP-1 synthesis by antiinflammatory cytokines and prostaglandin E2 in interleukin 17 stimulated human monocytes/macrophages. J Rheumatol 2001; 28:712-8.
66. Jovanovic DV, Martel-Pelletier J, Di Battista JA et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in humanmonocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum 2000; 43:1134-44.
67. Chabaud M, Garnero P, Dayer JM, Guerne PA, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000; 12:1092-9.
68. Chevrel G, Garnero P, Miossec P. Addition of interleukin 1 (IL1) and IL17 soluble receptors to a tumour necrosis factor alpha soluble receptor more effectively reduces the production of IL6 and macrophage inhibitory protein-3alpha and increases that of collagen in an in vitro model of rheumatoid synoviocyte activation. Ann Rheum Dis 2002; 61:730-3.
69. Van bezooijen RL, Farih-Sips HC, Papapoulos SE, Lowik CW. Interleukin-17: a new bone acting cytokine in vitro. J Bone Miner Res 1999; 14:1513-21.
70. Chabaud M, Page G, Miossec P. Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001; 167:6015-20.
71. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003; 100:5986-90.
72. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003; 171:6173-7.
73. Hoshino H, Laan M, Sjostrand M, Lotvall J, Skoogh BE, Linden A. Increased elastase and myeloperoxidase activity associated with neutrophil recruitment by IL-17 in airways in vivo. J Allergy Clin Immunol 2000; 105:143-9.
74. Happel KI, Zheng M, Young E et al. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol 2003; 170:4432-6.
75. Laan M, Cui ZH, Hoshino H et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162:2347-52.
76. Kawaguchi M, Kokubu F, Kuga H et al. Modulation of bronchial epithelial cells by IL-17. J Allergy Clin Immunol 2001; 108:804-9.
77. Rahman MS, Yamasaki A, Yang J, Shan L, Halayko AJ, Gounni AS. IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, JNK, P38) pathways. J Immunol 2006; 177:4064-71.
78. Laan M, Palmberg L, Larsson K, Linden A. Free, soluble interleukin-17 protein during severe inflammation in human airways. Eur Respir J 2002; 19:534-7.
79. Barczyk A, Pierzchala W, Sozanska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med 2003; 97:726-33.
80. Hellings PW, Kasran A, Liu Z et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol 2003; 28:42-50.
81. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160:1532-9.
82. Bank U, Reinhold D, Kunz D et al. Effects of interleukin-6 (IL-6) and transforming growth factor-beta (TGF-beta) on neutrophil elastase release. Inflammation 1995; 19:83-99.
83. Skold CM, Liu X, Umino T et al. Human neutrophil elastase augments fibroblast-mediated contraction of released collagen gels. Am J Respir Crit Care Med 1999; 159:1138-46.
84. Suzuki T, Wang W, Lin JT, Shirato K, Mitsuhashi H, Inoue H. Aerosolized human neutrophil elastase induces airway constriction and hyperresponsiveness with protection by intravenous pretreatment with half-length secretory leukoprotease inhibitor. Am J Respir Crit Care Med 1996; 153:1405-11.
85. Bank U, Kupper B, Reinhold D, Hoffmann T, Ansorge S. Evidence for a crucial role of neutrophil-derived serine proteases in the inactivation of interleukin-6 at sites of inflammation. FEBS Lett 1999; 461:235-40.
86. Chen Y, Thai P, Zhao YH, Ho YS, DeSouza MM, Wu R. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 2003; 278:17036-43.
87. Merville P, Pouteil-Noble C, Wijdenes J, Potaux L, Touraine JL, Banchereau J. Detection of single cells secreting IFN-gamma, IL-6, and IL-10 in irreversibly rejected human kidney allografts, and their modulation by IL-2 and IL-4. Transplantation 1993; 55:639-46.
88. Merville P, Pouteil-Noble C, Wijdenes J, Potaux L, Touraine JL, Banchereau J. Cells infiltrating rejected human kidney allografts secrete IFN-gamma, IL-6, and IL-10, and are modulated by IL-2 and IL-4. Transplant Proc 1993; 25:111-13.
89. Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 1996; 62:543-5.
90. Loong CC, Hsieh HG, Lui WY, Chen A, Lin CY. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002; 197:322-32.
91. van KC, Boonstra JG, Paape ME et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998; 9:1526-34.
92. Hsieh HG, Loong CC, Lin CY. Interleukin-17 induces src/MAPK cascades activation in human renal epithelial cells. Cytokine 2002; 19:159-74.
93. Vanaudenaerde BM, Dupont LJ, Wuyts WA et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 2006; 27:779-87.
94. Yoshida S, Haque A, Mizobuchi T et al. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant 2006; 6:724-35.
95. Li J, Simeoni E, Fleury S et al. Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model. Eur J Cardiothorac Surg 2006; 29:779-83.
96. Tang JL, Subbotin VM, Antonysamy MA, Troutt AB, Rao AS, Thomson AW. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 2001; 72:348-50.
97. Antonysamy MA, Fanslow WC, Fu F et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999; 162:577-84.
98. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000; 9:589-93.
99. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediat Inflammation 2005; 2005:273-9.
100. Homey B, eu-Nosjean MC, Wiesenborn A et al. Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000; 164:6621-32.
101. Matusevicius D, Kivisakk P, He B et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5:101-4.
102. Kurasawa K, Hirose K, Sano H et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000; 43:2455-63.
103. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52:65-70.
104. Biesinger B, Muller-Fleckenstein I, Simmer B et al. Stable growth transformation of human T lymphocytes by herpesvirus saimiri. Proc Natl Acad Sci USA 1992; 89:3116-9.
105. Patera AC, Pesnicak L, Bertin J, Cohen JI. Interleukin 17 modulates the immune response to vaccinia virus infection. Virology 2002; 299:56-63.
106. Knappe A, Hiller C, Niphuis H et al. The interleukin-17 gene of herpesvirus saimiri. J Virol 1998; 72:5797-801.
107. Luzza F, Parrello T, Monteleone G et al. Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol 2000; 165:5332-7.
108. Chung DR, Kasper DL, Panzo RJ et al. CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol 2003; 170:1958-63.
109. Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol 2004; 75:37-43.
110. Tartour E, Fossiez F, Joyeux I et al. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999; 59:3698-704.
111. Numasaki M, Fukushi J, Ono M et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101:2620-7.
112. Benchetrit F, Ciree A, Vives V et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002; 99:2114-21.
113. Hirahara N, Nio Y, Sasaki S et al. Reduced invasiveness and metastasis of Chinese hamster ovary cells transfected with human interleukin-17 gene. Anticancer Res 2000; 20:3137-42.
114. Kato T, Furumoto H, Ogura T et al. Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 2001; 282:735-8.
115. Steiner GE, Newman ME, Paikl D et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56:171-82.
116. Ciree A, Michel L, Camilleri-Broet S et al. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int J Cancer 2004; 112:113-20.
117. Wrobel T, Mazur G, Jazwiec B, Kuliczkowski K. Interleukin-17 in acute myeloid leukemia. J Cell Mol Med 2003; 7:472-4.
118. Numasaki M, Watanabe M, Suzuki T et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175:6177-89.
119. Grazia Roncarolo M, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212:28-50.
120. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182:207-14.
121. Lu L, Werneck MBF, Cantor H. The immunoregulatory effects of Qa-1. Immunol Rev 2006; 212:51-9.
122. Cortesini R, LeMaoult J, Ciubotariu R, Cortesini NSF. CD8+CD28-T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev 2001; 182:201-6.
123. Rifa'i M, Kawamoto Y, Nakashima I, Suzuki H. Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med 2004; 200:1123-34.
124. Hanninen A, Harrison LC. Gamma delta T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol Rev 2000; 173:109-19.
125. Zhang C, Zhang J, Tian ZG. The regulatory effect of natural killer cells: do 'NK-reg cells' exist? Cell Mol Immunol 2006; 3:241-54.
126. Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med 2006; 203:1851-8.
127. Ochando JC, Homma C, Yang Y et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7:652-62.
128. Ariel A, Fredman G, Sun YP et al. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat Immunol 2006; 7:1209-16.
129. Liu J, Liu Z, Witkowski P et al. Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. Transpl Immunol 2004; 13:239-47.
130. Suciu-Foca N, Manavalan JS, Scotto L et al. Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int Immunopharmacol 2005; 5:7-11.
131. Liu Z, Tugulea S, Cortesini R, Suciu-Foca N. Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+. Int Immunol 1998; 10:775-83.
132. Kapp JA, Honjo K, Kapp LM, Xu XY, Cozier A, Bucy RP. TCR transgenic CD8+ T cells activated in the presence of TGF{beta} express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection. Int Immunol 2006; 18:1549-62.
133. Zhang ZX, Young K, Zhang L. CD3+CD4-CD8- alphabeta-TCR+ T cell as immune regulatory cell. J Mol Med 2001; 79:419-27.
134. Zhang ZX, Yang L, Young KJ, DuTemple B, Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 2000; 6:782-9.
135. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
136. Sakaguchi S, Toda M, Asano M, Itoh M, Morse SS, Sakaguchi N. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J Autoimmun 1996; 9:211-20.
137. Chatila TA, Blaeser F, Ho N et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000; 106:R75-R81.
138. Wildin RS, Ramsdell F, Peake J et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001; 27:18-20.
139. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+) CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193:1303-10.
140. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+) CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001; 193:1285-94.
141. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188:287-96.
142. Wing K, Lindgren S, Kollberg G et al. CD4 T cell activation by myelin oligodendrocyte glycoprotein is suppressed by adult but not cord blood CD25+ T cells. Eur J Immunol 2003; 33:579-87.
143. Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006; 212:203-16.
144. Umetsu DT, DeKruyff RH. The regulation of allergy and asthma. Immunol Rev 2006; 212:238-55.
145. Rouse BT, Sarangi PP, Suvas S. Regulatory T cells in virus infections. Immunol Rev 2006; 212:272-86.
146. Belkaid Y, Blank RB, Suffia I. Natural regulatory T cells and parasites: a common quest for host homeostasis. Immunol Rev 2006; 212:287-300.
147. Waldmann H, Adams E, Fairchild P, Cobbold S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol Rev 2006; 212:301-13.
148. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev 2006; 212:256-71.
149. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004; 5:266-71.
150. Edinger M, Hoffmann P, Ermann J et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9:1144-50.
151. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+) CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196:389-99.
152. Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, Waldmann H. Both CD4(+) CD25(+) and CD4(+) CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol 2002; 168:5558-65.
153. Game DS, Hernandez-Fuentes MP, Chaudhry AN, Lechler RI. CD4+CD25+ regulatory T cells do not significantly contribute to direct pathway hyporesponsiveness in stable renal transplant patients. J Am Soc Nephrol 2003; 14:1652-61.
154. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61.
155. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-6.
156. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4:337-42.
157. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005; 22:329-41.
158. Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006; 24:209-26.
159. Walker MR, Kasprowicz DJ, Gersuk VH et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J Clin Invest 2003; 112:1437-43.
160. Gavin MA, Torgerson TR, Houston E et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006; 103:6659-64.
161. Liu W, Putnam AL, Xu-Yu Z et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203:1701-11.
162. Piccirillo CA, Shevach EM. Cutting edge. control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001; 167:1137-40.
163. Takahashi T, Kuniyasu Y, Toda M et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10:1969-80.
164. Romagnoli P, Hudrisier D, van Meerwijk JP. Preferential recognition of self antigens despite normal thymic deletion of CD4(+) CD25(+) regulatory T cells. J Immunol 2002; 168:1644-8.
165. Jordan MS, Boesteanu A, Reed AJ et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001; 2:301-6.
166. Cozzo C, Larkin J III, Caton AJ. Cutting edge. self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 2003; 171:5678-82.
167. Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A. Homeostasis and anergy of CD4(+) CD25(+) suppressor T cells in vivo. Nat Immunol 2002; 3:33-41.
168. Fisson S, rrasse-Jeze G, Litvinova E et al. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med 2003; 198:737-46.
169. Ng WF, Duggan PJ, Ponchel F et al. Human CD4(+) CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001; 98:2736-44.
170. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164:183-90.
171. Thornton AM, Piccirillo CA, Shevach EM. Activation requirements for the induction of CD4+CD25+ T cell suppressor function. Eur J Immunol 2004; 34:366-76.
172. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+) CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med 2002; 196:247-53.
173. Longhi MS, Hussain MJ, Mitry RR et al. Functional study of CD4+CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol 2006; 176:4484-91.
174. Nakamura K, Kitani A, Fuss I et al. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2004; 172:834-42.
175. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+) CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 2001; 194:629-44.
176. Ly D, Mi QS, Hussain S, Delovitch TL. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol 2006; 177:3695-704.
177. Lu LF, Lind EF, Gondek DC et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442:997-1002.
178. Duthoit CT, Mekala DJ, Alli RS, Geiger TL. Uncoupling of IL-2 signaling from cell cycle progression in naive CD4+ T cells by regulatory CD4+CD25+ T lymphocytes. J Immunol 2005; 174:155-63.
179. Duthoit CT, Nguyen P, Geiger TL. Antigen nonspecific suppression of T cell responses by activated stimulation-refractory CD4+ T cells. J Immunol 2004; 172:2238-46.
180. Sawitzki B, Kingsley CI, Oliveira V, Karim M, Herber M, Wood KJ. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005; 201:1925-35.
181. Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-tolerance maintained by CD25(+) CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192:303-10.
182. Read S, Greenwald R, Izcue A et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006; 177:4376-83.
183. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+) CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192:295-302.
184. Jago CB, Yates J, Camara NO, Lechler RI, Lombardi G. Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol 2004; 136:463-71.
185. Levings MK, Sangregorio R, Roncarolo MG. Human CD25(+) CD4(+) T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001; 193:1295-302.
186. Sansom DM, Walker LSK. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 2006; 212:131-48.
187. Kawahata K, Misaki Y, Yamauchi M et al. Generation of CD4(+) CD25(+) regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from non-autoreactive T cells by endogenous TCR expression. J Immunol 2002; 168:4399-405.
188. Pennington DJ, Silva-Santos B, Silberzahn T et al. Early events in the thymus affect the balance of effector and regulatory T cells. Nature 2006; 444:1073-7.
189. Tellier J, van Meerwijk JP, Romagnoli P. An MHC-linked locus modulates thymic differentiation of CD4+CD25+Foxp3+ regulatory T lymphocytes. Int Immunol 2006; 18:1509-19.
190. Bayer AL, Yu A, Adeegbe D, Malek TR. Essential role for interleukin-2 for CD4(+) CD25(+) T regulatory cell development during the neonatal period. J Exp Med 2005; 201:769-77.
191. Tang Q, Henriksen KJ, Boden EK et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003; 171:3348-52.
192. Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 2006; 6:1084-5.
193. Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354:1691-5.
194. Hakim FT, Memon SA, Cepeda R et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest 2005; 115:930-9.
195. Mackall CL, Gress RE. Thymic aging and T-cell regeneration. Immunol Rev 1997; 160:91-102.
196. Zhang H, Chua KS, Guimond M et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005; 11:1238-43.
197. McHugh RS, Shevach EM. Cutting edge. depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol 2002; 168:5979-83.
198. Barthlott T, Kassiotis G, Stockinger B. T cell regulation as a side effect of homeostasis and competition. J Exp Med 2003; 197:451-60.
199. Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ. CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion. J Immunol 2004; 173:7259-68.
200. Liang S, Alard P, Zhao Y, Parnell S, Clark SL, Kosiewicz MM. Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med 2005; 201:127-37.
201. Almeida AR, Zaragoza B, Freitas AA. Competition controls the rate of transition between the peripheral pools of CD4+. Int Immunol 2006; 18:1607-13.
202. Almeida AR, Zaragoza B, Freitas AA. Indexation as a novel mechanism of lymphocyte homeostasis. the number of CD4+CD25+ regulatory T cells is indexed to the number of IL-2-producing cells. J Immunol 2006; 177:192-200.
203. Vukmanovic-Stejic M, Zhang Y, Cook JE et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006; 116:2423-33.
204. Yu A, Malek TR. Selective availability of IL-2 is amajor determinant controlling the production of CD4+CD25+Foxp3+ T regulatory cells. J Immunol 2006; 177:5115-21.
205. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:665-74.
206. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 2005; 202:1375-86.
207. Thorstenson KM, Khoruts A. Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J Immunol 2001; 167:188-95.
208. Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004; 199:1401-8.
209. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, von Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005; 6:1219-27.
210. Grimbert P, Bouguermouh S, Baba N et al. Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+. J Immunol 2006; 177:3534-41.
211. Huber S, Schramm C, Lehr HA et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 2004; 173:6526-31.
212. Schramm C, Huber S, Protschka M et al. TGFbeta regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo. Int Immunol 2004; 16:1241-9.
213. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005; 201:1061-7.
214. Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86.
215. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+. J Immunol 2004; 172:5149-53.
216. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13:715-25.
217. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46.
218. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995; 181:381-6.
219. Constantinescu CS, Wysocka M, Hilliard B et al. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. J Immunol 1998; 161:5097-104.
220. Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421:744-8.
221. Murphy CA, Langrish CL, Chen Y et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198:1951-7.
222. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278:1910-4.
223. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123-32.
224. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6:1133-41.
225. Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, van Dissel JT. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 2002; 32:97-105.
226. Verreck FABT, Langenberg DM et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proc Natl Acad Sci USA 2004; 101:4560-5.
227. Uhlig HH, McKenzie BS, Hue S et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006; 25:309-18.
228. Parham C, Chirica M, Timans J et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002; 168:5699-708.
229. Hoeve MA, de Savage ND, BT et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006; 36:661-70.
230. Rangachari M, Mauermann N, Marty RR et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 2006; 203:2009-19.